Compare Manchester United PLC (MANU) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Mesoblast Limited — how do they compare? Manchester United PLC trades at $20.51 (market cap $3.51B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Manchester United PLC is far larger — about 2× Mesoblast Limited's market cap, and Manchester United PLC pays a 1.26% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manchester United PLC for 109 Days and Mesoblast Limited for 15 Days on average.
| MANU | MESO | |
|---|---|---|
Market Cap | $3.51B | $1.75B |
Volume | 412,769 | 239,027 |
Sector | Media | Health |
52-Week High | $24.19 | $20.96 |
52-Week Low | $15.20 | $13.19 |
Typical Hold Time | 109 Days | 15 Days |
Enterprise Value | $4.33B | $1.83B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $20.51, up 1.28% with a bearish technical outlook. The company reported mixed Q4 2026 results, missing EPS estimates but beating revenue expectations. Despite posting a net loss of $33.02M in 2025, revenue grew to $666.51M. Analyst sentiment is divided with 40% buy ratings, while institutional ownership shows confidence with Gabelli Funds increasing its stake by 26.2% in Q1 2026.
MANU presents a speculative opportunity given its discounted valuation relative to franchise worth, but faces significant profitability challenges. The stock's upside depends on operational improvements and Champions League performance, while persistent losses and high debt levels remain key risks for investors.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
